Oxytocin is approved by the U.S. FDA as a prescription medication. Use requires evaluation and a prescription from a licensed healthcare provider.
Status as of July 16, 2026
Oxytocin does two mechanical jobs in reproduction, and the published record on both rests on human clinical evidence rather than extrapolation: it contracts the uterus and it ejects milk. Both actions run through the same nine-amino-acid peptide, released in pulses from the posterior pituitary, acting on smooth muscle in one organ and muscle-like cells in the other. What the record does not support is the popular idea that oxytocin starts labor or makes milk, and both misreadings carry real consequences in a delivery room.
Oxytocin is a nine-amino-acid peptide released in pulses from the posterior pituitary that contracts myometrial and myoepithelial cells, and the World Health Organization recommends 10 international units of it as the uterotonic of choice for every birth.
The hormone that contracts the uterus is manufactured in the brain, not in the reproductive tract. Magnocellular neurons in the hypothalamus build it, long axons carry it to the posterior pituitary for storage, and the bloodstream delivers it to the uterus with no specialized route. That detour matters clinically, because the decidua, chorion, amnion, and placenta also make the peptide locally, which is why a maternal plasma level is a poor proxy for how much oxytocin the uterus is actually seeing.
Oxytocin is synthesized in the hypothalamus and only stored in the posterior pituitary, which is a release site rather than a true gland, and it reaches the uterus as an endocrine signal with a plasma half-life on the order of one to six minutes.
The pregnant uterus does not become responsive to oxytocin by receiving more of it. It becomes responsive by growing more receptors, under estrogen's promotion and progesterone's restraint. That single fact explains why an infusion at twenty-four weeks often produces very little while the same dose at term produces powerful labor, and why a uterus driven hard for many hours becomes progressively harder to move.
Myometrial oxytocin receptor density rises from near-negligible in the non-pregnant uterus to a level commonly reported at a hundredfold or more above baseline by term, while maternal plasma oxytocin does not surge in the hours before human labor begins.
Named for the Canadian physiologist James Ferguson, who described it in rabbits in 1941, this reflex is the mechanism by which labor accelerates itself. The loop is unusual because it is positive: the output amplifies the stimulus instead of counteracting it, so the system escalates rather than settling toward a set point. Human physiology tolerates that arrangement only where a process needs to run to completion, which is why the short list of examples is essentially labor, the clotting cascade, and the action potential upstroke.
The Ferguson reflex is one of a very short list of genuine positive feedback loops in human physiology, alongside the clotting cascade and the action potential upstroke, and it terminates only when delivery removes the stretch stimulus that drives it.
Two uses get lumped together but are distinct: induction starts labor in a uterus that is not in labor, while augmentation strengthens contractions in a labor already underway but progressing inadequately. The drug is the same in both, and chemically identical to the endogenous hormone, since Vincent du Vigneaud determined the sequence and synthesized it in 1953, the first peptide hormone ever made in a laboratory. The whole difference sits in delivery, because a continuous infusion replaces what the body would release as discrete pulses, and individual uterine sensitivity varies by more than an order of magnitude.
| Regimen feature | Low-dose | High-dose |
|---|---|---|
| Reported starting rate | 0.5 to 2 milliunits/min | ~6 milliunits/min |
| Reported increment | 1 to 2 milliunits | 3 to 6 milliunits |
| Interval | Every 15 to 40 minutes | Similar intervals |
| Reported trade-off | Fewer tachysystole events | Somewhat shorter labor, more tachysystole |
Plasma concentration takes roughly forty minutes to plateau at any fixed infusion rate, so the reported titration endpoint is a contraction pattern of about three to five contractions in ten minutes with adequate relaxation, not a target dose.
A separated placenta leaves a raw bed of open spiral arteries carrying close to six hundred milliliters of blood per minute, and clotting is far too slow to handle that. What stops the bleeding is muscle rather than coagulation: interlacing myometrial bundles kink and compress the vessels running between them, an arrangement described since the nineteenth century as the living ligatures of the uterus. A woman with perfectly normal clotting can still exsanguinate from a soft uterus.
Uterine atony accounts for roughly seventy to eighty percent of primary postpartum hemorrhage, a leading direct cause of maternal death worldwide, which is why the World Health Organization recommends a prophylactic uterotonic for every birth with 10 international units of oxytocin the recommended agent.
Milk is pushed out, not sucked out. An infant cannot generate enough negative pressure to empty the alveoli where milk sits, so oxytocin has to expel it toward the nipple. Because the pathway runs through the brain rather than staying local, it is readily conditioned by an infant's cry and readily inhibited by pain or acute stress, which is how a mother with a full breast can be genuinely unable to release the milk in it.
Milk is ejected by oxytocin-driven myoepithelial contraction roughly thirty to sixty seconds into a feed rather than drawn out by infant suction, and in an animal model, mice lacking the oxytocin gene deliver normally and fill with milk while their pups starve.
Only moves it, and the distinction is worth stating flatly because conflating the two hormones is one of the most common misunderstandings in lactation. Prolactin makes milk; oxytocin moves milk. The two failure modes they produce look identical from the outside, since both present as a hungry infant and a disappointing feed, but they are opposite problems with opposite solutions.
| Criteria | Prolactin | Oxytocin |
|---|---|---|
| Source | Lactotrophs, anterior pituitary | Hypothalamus, stored in posterior pituitary |
| Target cell | Alveolar secretory epithelium | Myoepithelial cells |
| Function | Synthesis of lactose, casein, milk fat | Ejection only, no synthetic function |
| Release trigger | Progesterone withdrawal at placental delivery | Suckling, and conditioned cues |
| Failure mode | Little milk produced | Milk present but not released |
Prolactin from the anterior pituitary drives milk synthesis while oxytocin from the posterior pituitary only ejects milk already made, and intranasal oxytocin, marketed for decades to assist let-down, is no longer available as an FDA-approved product in the United States.
The dominant hazard is mechanical, not toxic. Fetal oxygen delivery happens entirely in the gaps between contractions, when the intervillous space refills with maternal blood, so the danger is the loss of the interval rather than the contraction itself. That single insight orders the whole risk profile, and it is why a drug this common, whose errors reach two patients at once, carries a high-alert designation managed with standardized concentrations and pre-printed order sets rather than individual judgment.
Tachysystole, defined as more than five contractions in ten minutes averaged over a thirty-minute window, is oxytocin's leading complication because fetal oxygen delivery happens entirely in the relaxation intervals it erases.
Approved labeling in the United States is narrower than everyday practice might suggest, and the gap is instructive rather than accidental. Labeling and contemporary practice guidance are different instruments updated on different timescales, so the package insert and the professional society position can disagree for years while both remain current.
United States labeling for oxytocin injection carries an Important Notice at the head of its Indications and Usage section stating the drug is not indicated for elective induction of labor, while the World Health Organization recommends 10 international units in the third stage and lists oxytocin as an essential medicine.
Structure dictates route. Oxytocin is a nonapeptide of roughly one thousand daltons, folded into a six-residue ring closed by a disulfide bridge, and swallowing it fails on two independent counts: gastric and pancreatic proteases cleave it into fragments, and whatever survives is too large and too hydrophilic to cross the intestinal epithelium in meaningful quantity. Oral bioavailability is effectively zero, a constraint shared by essentially every peptide hormone including insulin, so the two injected routes divide the clinical work between them.
| Criteria | Intravenous infusion | Intramuscular injection |
|---|---|---|
| Onset | ~3 to 5 minutes | Comparable |
| Steady state | ~40 minutes at a fixed rate | Not applicable |
| Duration | Washes out within minutes of stopping | Persists 2 to 3 hours |
| Reversibility | Titratable and reversible | Cannot be dialed back |
| Where the record places it | Induction and augmentation | Third-stage prophylaxis |
Oxytocin's peptide structure gives it effectively zero oral bioavailability, so it is given by injection, and its aqueous solution degrades with heat and requires WHO cold-chain storage at two to eight degrees Celsius, the constraint that motivated heat-stable carbetocin.
Educational use only. This article describes what the published scientific and clinical literature reports about Oxytocin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
